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ARTICLE
3D extracellular matrix microenvironment
in bioengineered tissue models of primary
pediatric and adult brain tumors
Disha Sood 1, Min Tang-Schomer 2,3, Dimitra Pouli 1,4, Craig Mizzoni1, Nicole Raia 1, Albert Tai 5,
Knarik Arkun 6, Julian Wu7, Lauren D. Black III 1, Bjorn Scheffler 8,9, Irene Georgakoudi 1,
Dennis A. Steindler 8,10 & David L. Kaplan 1*
Dynamic alterations in the unique brain extracellular matrix (ECM) are involved in malignant
brain tumors. Yet studies of brain ECM roles in tumor cell behavior have been difficult due to
lack of access to the human brain. We present a tunable 3D bioengineered brain tissue
platform by integrating microenvironmental cues of native brain-derived ECMs and live
imaging to systematically evaluate patient-derived brain tumor responses. Using pediatric
ependymoma and adult glioblastoma as examples, the 3D brain ECM-containing micro-
environment with a balance of cell-cell and cell-matrix interactions supports distinctive
phenotypes associated with tumor type-specific and ECM-dependent patterns in the tumor
cells’ transcriptomic and release profiles. Label-free metabolic imaging of the composite
model structure identifies metabolically distinct sub-populations within a tumor type and
captures extracellular lipid-containing droplets with potential implications in drug response.
The versatile bioengineered 3D tumor tissue system sets the stage for mechanistic studies
deciphering microenvironmental role in brain tumor progression.
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Many brain tumors have dismal prognosis, especiallyglioblastoma (GBM) and those that typically occur inyoung children, such as ependymoma. Genome-wide
profiling of these tumors have revealed increasing tumor subtypes
and intra-tumor heterogeneities1,2. For example, it is found that
brain tumor types are highly dependent on a patient’s age and
brain region3; brain region/age-matched xenograft mouse
models can better recapitulate the tumor cell biology than grafts
in non-brain microenvironment4. Although brain-ECM recep-
tors/ligands are increasingly been characterized5–7; brain-ECM
studies in general have been difficult, in part, due to lack of access
to specific matrix components for in vitro testing. We have
attempted to develop an in vitro platform system to examine the
dynamic interactions of a brain-ECM-containing microenviron-
ment with different primary brain tumors. GBM, the most pre-
valent primary infiltrating glioma in adults, has a dismal
prognosis with a median survival of 1–2 years post diagnosis8.
Anaplastic ependymoma, a rapidly growing glioma arising from
ependymal cells lining the ventricles, is among the three most
common malignant pediatric brain tumors9. The two distinctive
tumor types share little in common with regards to their biology
other than the brain origin; therefore allowing for the distinction
of tumor-specific vs. ECM-specific responses under the same
ECM microenvironment.
ECM guides gene expression patterns within cells by influen-
cing the cytoskeletal geometry and the chromatin-nuclear matrix
interactions, and in turn cells impact the ECM, as established
by the ‘dynamic reciprocity’ model10. The instructive role of
basement membrane hydrogel microenvironment in directing
epithelial tissue-specific responses has been well described in
the context of mammary gland and breast tumorigenesis10,11.
In comparison, few studies have directly examined the dynamic
changes of brain ECM during development and in disease states7.
The brain has a unique ECM composition with proteoglycans as a
major component, including chondroitin sulfate proteoglycans
(CSPGs), levels of which change during development7. Altera-
tions in brain ECM associated with brain tumors include
abnormally high levels of hyaluronan (HA) and/or collagens12,13
and altered expression of specific CSPGs14. While several CSPGs
are upregulated in GBM progression7, CSPGs may also prevent
diffuse invasion of tumor cells15. These studies have provided
evidence of brain-ECM involvement in tumor progression; yet it
is unclear how different tumors alter their ECM environment by
the tumor cells’ reciprocal signaling. In order to understand the
dynamic cell-ECM interactions, it is critical to separately define
the contributions of ECM components towards brain tumor
development, progression, and tumor-type-specific responses. In
our in vitro platform system, we incorporate developmentally
sourced brain-ECM cues, with the aim of capturing some of these
dynamic tumor cell-ECM responses.
Current systems for investigating brain tumor biology include
2D monolayer cultures, neurosphere/organotypic cultures and
animal models; each of which have limitations. Conventional 2D
cell cultures lack a 3D ECM environment that is necessary for
studying tumor cell-microenvironment interactions, while com-
monly used animal models are cost intensive, low-throughput,
and difficult to translate to humans16,17. Additionally, existing 3D
brain tumor models have primarily focused on mechanical effects
of the matrix towards tumor growth and have relied on estab-
lished tumor cell lines such as U87, U-251 MG16,18,19, which lack
the cellular and structural heterogeneity present in an in vivo
tumor. Also, despite in vivo malignancy, in vitro culture has not
been successful with many cell lines20, making the need for brain-
mimicking model systems particularly acute. Some patient-
derived 3D tumor models, such as spheroids/organoids have
been developed; however, they lack brain-specific ECM, are
challenging to culture long-term due to expanding necrotic
cores and a noticeable decline in growth, and have limited
tunability17,21. Therefore, a brain-mimicking tumor model
requires the combination of genuine tumor cells and brain-ECM-
containing microenvironment.
Towards that end, we present a tunable platform to system-
atically examine the interactions of 3D brain-ECM-containing
microenvironment with patient-derived brain tumor cells. We
previously developed a 3D bioengineered brain tissue model
based on a donut-shaped silk fibroin protein scaffold infused with
ECM hydrogels. The compartmentalized model design permits
region-specific primary neuronal growth in the soft hydrogel
region vs. the stiffer scaffold outer-ring region22. In the current
study, we leveraged the modular assembly for investigation of
different ECM components; for example, supplement of fetal or
adult porcine brain-derived ECM in a base hydrogel towards
primary tumor growth/migration. Additionally, we integrated
high resolution two-photon metabolic imaging into the bioengi-
neered tissue model for real-time tracking of patient-derived
tumor growth in 3D. Quantitative readouts of metabolic activity
at cellular/subcellular features over several hundred microns of
depth can be extracted from analysis of two-photon excited
fluorescence (TPEF) images that rely on the natural fluorescence
of two key metabolic co-enzymes, NADH (Nicotinamide adenine
dinucleotide) and FAD (Flavin adenine dinucleotide) without the
need for tissue processing or interference with cell viability or
function23–25. The ability of the optical redox ratio to report
changes in the redox state of cells has been validated with mass
spectrometry measurements and its sensitivity to metabolic per-
turbations has been demonstrated24,25. For example, a high redox
ratio (FAD/FAD+NADH) has been associated with enhanced
glutaminolysis, uncoupling, and oxidative stress/cell apoptosis
while a lower redox ratio with upregulated glycolysis and fatty
acid oxidation/synthesis23–26.
Here, we establish utility of the generated 3D bioengineered
brain tumor system using pediatric anaplastic ependymoma and
adult GBM patient-derived tumor cells as case studies. Tumor
growth and drug responses in different microenvironments were
assessed longitudinally using TPEF imaging, high throughput
matrix metalloproteinases (MMPs)/cytokine release microarrays,
and transcriptomic profiling (Fig. 1). We present a versatile brain
tumor culture system with a unique advantage to tune the ECM
microenvironment and simultaneously monitor the reciprocal
signaling with the tumor cells. Our findings of tumor-type-
specific ECM response demonstrate the potential for future
mechanistic studies along with co-culture of tumor cells with
healthy brain cells (Fig. 1). Thus, this platform, combining
bioengineered scaffolds to provide high surface area to volume 3D
environment for tumor cells and live imaging approaches, can
offer opportunities for comprehensive understanding of the brain
tumor-ECM microenvironment.
Results
Patient tumors displayed ECM-dependent metabolic activity.
We sought to decipher the role of brain-derived ECM from
varying developmental stages on brain tumor progression
in vitro, to determine more optimal matrix conditions than
existing methods for primary tumor culture. A decellularization
approach was undertaken since little is known about brain ECM
during development and ECM proteins are mostly conserved over
species, such that porcine brains can be used to extract a mixture
of native brain-ECM27. Additionally, in this study we employ
a 3D donut-shaped scaffold-based approach to allow for simul-
taneous maintenance of both non-migratory and adherent
migratory cell populations.
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Pediatric and adult patient-derived anaplastic ependymoma
and GBM, respectively, were cultured in silk scaffold-based 3D
constructs infused with either collagen type I (CLG1, shown to be
compatible with brain cells28) or hyaluronic acid (HA, a defined
brain-ECM component) hydrogels supplemented with native
brain-derived ECM. Figure 2a, b shows infiltration towards the
central hydrogel window of the 3D construct by GFAP-stained
ependymoma cells. Ependymoma cells migrated as single cells
into the hydrogel window, with faster migration qualitatively
observed in the fetal ECM-enriched constructs (Fig. 2a, b). GBM,
on the other hand, grew primarily as spheres within the silk
scaffold-hydrogel constructs along with visibly more disperse cells
within the fetal ECM-enriched hydrogels (Fig. 2a, c, Supplemen-
tary Fig. 1); however, there was little to no migration of GBM cells
within the central window of CLG1-based constructs at earlier
time points. When the same GBM was cultured in HA-based
hydrogels (known to be abnormally high in GBM13), greater
migration within shorter time frames was evident in the HA
hydrogels, particularly within the fetal ECM-enriched HA
cultures, at 1 month post-gel addition (Supplementary Fig. 2).
Spheres of fibrous tumor were seen to migrate outwards from the
outer rim of the scaffold forming what we define as the outer edge
gel population (Supplementary Fig. 2 inset). This outward
migration pattern was not noticed in collagen I hydrogels.
Multiple spheres of varying sizes were observed within the 3D
constructs for GBM, as opposed to all the spheres joining into one
large mass when cultured by conventional scaffold-free cultures,
pointing towards a competition between cell-cell and cell-matrix
interactions in the 3D constructs with relevance to in vivo
scenarios.
We employed different assays to determine the possible
metabolic activities underlying the tumor-type-specific pheno-
types. Despite using two completely distinct brain tumors, the
cultured ependymoma and GBM exhibited similar trends in their
metabolic activities in response to the infused hydrogel matrices.
Analogous bulk viability was observed across different ECM
conditions for both ependymoma and GBM (Fig. 2d, e).
However, significantly higher lactate dehydrogenase (LDH)
release was noted in the fetal ECM-enriched constructs in
comparison to other ECMs for both tumor types (Fig. 2f–h).
Similarly, when different base hydrogels of CLG1 or HA were
utilized, LDH release showed higher levels in fetal ECM-enriched
compared to unsupplemented constructs (Fig. 2g, h). These
results indicate that the presence of fetal ECM promotes tumor
cell metabolism for GBM as well as ependymoma.
Because certain ECM components such as CSPGs are known to
inhibit tumor infiltration15, we suspected that the phenotypic
differences between GBM and ependymoma despite the same
starting ECM may relate to the modulation of tumor-secreted
matrix components. Therefore, we examined CSPG levels in
different tumor cultures. The released CSPGs were significantly
higher in the fetal ECM-enriched constructs for ependymoma
(Fig. 2i), but no CSPGs were detected from cultured GBM under
any conditions at tested time points (1week–7.5 months).
Together, these data showed that in the same starting
bioengineered microenvironment, the different tumor-type-
specific phenotypes (i.e., more migratory ependymoma vs. sphere
GBM) may attribute to tumor-released signals that can be
identified by various non-destructive solution-based assays.
Because primary tumor cases are often unpredictable; the fact
that these 3D cultures can be monitored with specific live assays
allowed for individualized studies tailored for tumor-type/stages.
Based on the robust growth in fetal ECM-containing condition
for both tumor types, we focused on this condition and examined
their transcriptomic and proteomic characteristics.
Transcriptomic profile clustered based on culture conditions.
RNA sequencing of the 3D bioengineered tumor cultures
was performed to determine genome-wide expression (tran-
scriptomic) changes under different 3D tissue model conditions
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Fig. 1 Versatile 3D bioengineered brain tumor tissue model. Multi-level interrogation into the role of extracellular matrix and microenvironment on tumor
growth. Middle panel—Tumor cells seeded as single cells post dissociation from the excised tumor, migrate as single cells towards the central hydrogel
window or revert back to sphere-like morphology within the scaffold depending on original tumor characteristics. Left panel—Introduction of suitable ECM
and soluble cues to maintain tumor characteristics and drug screening. Right panel—Multiscale interrogation of the culture system via transcriptomic and
genomic profiling, and live metabolic imaging. Co-culture of tumor cells with healthy differentiated human neural stem cells (hNSCs)
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tumor culture changes in terms of gene expression pertaining to
media conditions, ECM, and time in culture.
For ependymoma, clustering and principal component analysis
(PCA) was performed across three experimental categories; media
type (FBS vs. serum free), time in culture (0.5, 1.5, 4 months), and
ECM (fetal brain-ECM-enriched collagen I- FECM, adult brain-
ECM-enriched collagen I-AECM or plain collagen I-CLG1)
(Fig. 3). When compared between media types, 3D tissue models
in serum-free media showed more similar transcriptomic profiles
(i.e., clustered together) when compared to those in serum-
containing media. (Fig. 3a, b). We also noticed that primary
pediatric ependymoma cells had difficulty thriving in FBS-
containing media. On the other hand, when cultured in a


















































































































































FECM+CLG1 AECM+CLG1 CLG1 FECM+CLG1 AECM+CLG1 CLG1 FECM+CLG1 AECM+CLG1 CLG1
FECM+CLG1 AECM+CLG1 CLG1FECM+CLG1 AECM+CLG1 CLG1 FECM+HA AECM+HA HA
Fig. 2 Patient-derived anaplastic ependymoma and glioblastoma in silk scaffold-based 3D constructs. a Brightfield image of donut-shaped silk scaffold seeded
with tumor cells and infused with hydrogel. Systems infused with either collagen I (CLG1) or hyaluronic acid (HA) hydrogels supplemented with porcine brain-
derived ECM (Fetal ECM: FECM, Adult ECM: AECM), cultured in chemically defined media lacking FBS. The middle circular window indicated by the yellow
outline demarcates a distinct region within the construct that is exclusively hydrogel filled and not initially seeded with cells but where tumor cells can migrate.
b Migration of anaplastic ependymoma cells at 2 week shown by GFAP staining within the middle hydrogel window of the 3D donut-shaped constructs.
Presence of GFAP-positive glial cells matched histopathology reports. Scale bar, 100 μm, Max projection of z-stack imaged in Leica SP8 confocal. c Growth of
glioblastoma (GBM) at 3 week shown by live calcein and dead red staining within the ring portion of the 3D donut-shaped constructs. GBM grew more as
spheres and did not infiltrate the middle window at earlier time points in CLG1-based hydrogels. Scale bar, 300 μm, Max projection of z-stack imaged in Leica
SP8 confocal. Wst-1 viability assay at 2 week in 3D ependymoma d and 1.5 mo GBM e silk-CLG1 cultures, respectively indicating similar viability across all
ECM conditions. f Lactate dehydrogenase (LDH) release assay at 2 week in 3D ependymoma cultures. Statistically significant difference in the LDH release in
FECM condition in comparison to AECM or CLG1 alone. g LDH release assay at 1.5 mo in 3D GBM silk-CLG1 cultures, showing statistically significant (higher)
LDH release in FECM condition assuming a Gaussian distribution. h LDH release assay in 3D GBM silk-HA cultures, showing statistically significant (higher)
LDH release in FECM condition at 1 mo. i Chondroitin sulfate proteoglycan (CSPG) release observed to be statistically significant (higher) in the FECM and
AECM containing constructs at 3 week in 3D ependymoma cultures. Ordinary one-way ANOVA with Tukey’s post-hoc, F > 6.958, *p < 0.0412, **p=0.0056,
***p=0.0001, ****p < 0.0001. Error bars indicate mean ± s.d, Source data are provided as a Source Data file
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ependymoma cells with in vivo-like rosette morphology29,
increased metabolic activity and decreased drug response;
consistent with recent reports of serum rendering enhanced drug
sensitivity to tumor cells30 (Supplementary Fig. 3). Within the
serum-free sub-group, fetal ECM cultures segregated away from
the adult ECM and unsupplemented collagen conditions at both
0.5 and 4 months in culture (Fig. 3a). When compared between
time points, the longest time point (4 months) samples showed
different transcriptomic profiles than earlier time points (0.5 and
1.5 months) (Fig. 3c, d). Finally, when compared between ECM
types, the unsupplemented collagen condition separated from
fetal and adult ECM conditions, which overall had similar gene
expression profiles regardless of time point or media type
(Fig. 3e). The heatmap results of transcriptomic profiles were
consistent with clustering on the PCA plots, where the distance
between samples on the plot is proportional to the mean fold
change of gene expression differences between samples (Fig. 3b,
d, f). Specific genes consistent with studies of human ependy-
moma samples showed expression level changes4, including
upregulated insulin growth factor 2 (IGF2), vascular endothelial
growth factor-A (VEGFA), vimentin, matrix metalloproteinase 9
(MMP9) and MMP231 and downregulated mature neuronal
maker, microtubule associated protein 2 (MAP2) in fetal ECM-
enriched cultures when compared to unsupplemented collagen
cultures (Supplementary Figs. 4, 5).
For the GBM cultures, fetal and adult ECM constructs also
showed more similarity to each other than to the unsupplemen-
ted collagen I constructs, as seen in heat maps with dendrogram
clustering alongside PCA plots (Fig. 4a, b). Fetal ECM-enriched
cultures supported upregulation of genes found to be associated
with GBM human samples including epidermal growth factor
receptor (EGFR)32, insulin growth factor binding protein 2
(IGFBP2)33 and MMP234, compared to other ECM conditions
(Supplementary Fig. 6). We additionally validated higher
expression of EGFR (~1.5 fold, p < 0.05) in fetal ECM-enriched
GBM cultures relative to unsupplemented collagen I by PCR
(Supplementary Fig. 7).
Together, these data showed that the 3D model’s culture
conditions affect tumor tissue’s gene expression profiles, and
suggest that these genetic changes underlie the phenotypic
outcomes of tumor growth in the different microenvironments.
In particular, 3D tissue models with brain-ECM-containing
a c e











































































































































































































Fig. 3 RNA-sequencing data for anaplastic ependymoma 3D bioengineered cultures. a–c Heatmap along with cluster dendrograms focusing on time in
culture, media type and extracellular matrix categories, respectively, generated using FPKM (Reads Per Kilobase of transcript per Million mapped reads)
values with a false discovery rate q < 0.2 or p-values < or= 0.005. d–f Principal component analysis (PCA) plots corresponding to a, b and c clustering,
respectively. FECM- Fetal ECM+ collagen I, AECM- Adult ECM+ Collagen I, CLG1-Collagen I. a, b: False discovery rate (q)= 0.04, p-value= 0.001; c/d:
q= 0.04, p= 0.005; e, f: q= 0.2, p= 0.0002; n= 1 per condition. Source data are provided as Supplementary Data 1
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hydrogels (i.e., derived from fetal or adult brain sources) differed
from those with non-brain-derived ECM hydrogels (i.e., unsup-
plemented collagen I) for both ependymoma and GBM.
Tumor-type-specific interactions with ECM microenviron-
ments. Cytokines released from the 3D bioengineered ependy-
moma and GBM cultures were examined to determine impact of
the microenvironment on tumor-secreted factors and also tumor-
type-specific paracrine signaling. We studied ECM-associated
profiles including MMPs, tissue inhibitors of MMPs (TIMPs),
and cytokines with culture supernatants of 3D tumor models.
With ependymoma tissue models, higher (2–4 fold) MMP-9
release was observed in cultures containing fetal ECM, while
TIMPs were detected at much lower levels overall (0.3–0.5 fold)
compared to other ECM types (Fig. 5a). This feature correlated
with the high metabolic activity (LDH assay) and tissue viability
(Fig. 2d, f), the highly migratory phenotype (Fig. 2b) and tumor-
released CSPG (Fig. 2i) of this group.
With GBM tissue models, TIMPs were upregulated across all
ECM conditions as opposed to MMPs (Fig. 5b, Supplementary
Fig. 8a). In particular, TIMP2 was elevated in fetal ECM-enriched
cultures (~2.5 fold) over unsupplemented CLG1 or HA cultures
(Fig. 5c, d). When either CLG1 or HA was used as a base
hydrogel in GBM cultures, fetal ECM supplement showed the
upregulation of factors that are associated with tumor aggres-
siveness and growth, including IL-6, IGFBP2, MCP-1, TIMP-2,
TIMP-1, MIG, IL-10, HGF, and NT-333–36 (Fig. 5c, d,
Supplementary Fig. 8b, c).
Real-time tracking of 3D tumor growth with metabolic ima-
ging. GBM is known to harbor metabolically heterogeneous cell
populations that respond differentially to chemotherapy drugs37,
which is imperative to recapitulate in in vitro models38,39. We
sought to determine the presence of such populations in the 3D
tumor models and their drug responses using high resolution
metabolic imaging to dynamically monitor the tumor growth.
First, we compared GBM growth in HA vs. CLG1 infused cell-
seeded scaffolds. Upon hydrogel introduction at 5.5 months, and
post 1.5 month of hydrogel infusion, macroscopic spheres were
visible in both HA and CLG1 conditions (Fig. 6a, yellow arrows).
Endogenous imaging of metabolic enzymes indicated metabolic
differences between HA and CLG1 conditions, with a significantly
higher redox ratio (FAD/FAD+NADH) in CLG1 condition that
is visually manifested as more intense red hues in the redox-
scaled color-coded images and quantified by the optical redox
ratio (Fig. 6b, c).
The HA condition was evaluated longitudinally alongside two
additional conditions; fetal brain-ECM-enriched HA (FECM-
HA) and adult brain-ECM-enriched HA (AECM-HA). Though
tumor cells were only seeded in the ring-shaped silk scaffold;
within the first 2 weeks post-gel addition, tumor cell growth was
observed in the gel portion extending from the outer edges of the
brain-ECM-enriched HA-containing silk scaffolds (noticed via
daily inspections under bright-field) (Supplementary Fig. 2).We
refer to this newly arisen population observed under bright-field
(indicated by yellow arrows in Fig. 7a) and via metabolic imaging
(Fig. 7b) as the outer edge gel cell population. Although similar in
redox ratio hues, varied structural organization of the cellular
populations was visible in the outer edge gel depending on the
ECM supplementation. These cells showed sphere morphology in
pure HA gels, while a greater tendency of cellular spreading was
observed in brain-ECM-enriched HA gels, suggesting a locally
infiltrative phenotype (Fig. 7b). The locally infiltrative cell
populations (indicated by yellow arrows in Fig. 7a) had an
overall lower redox ratio qualitatively observed by darker blue
hues and quantified by the optical redox ratio (Fig. 7b, left
column; Fig. 7c, black data points) in comparison to the immobile
cell populations within the bulk of the scaffold region (Fig. 7b,
right column; Fig. 7c, black data points), likely indicating a more
proliferative/glycolytic phenotype.
Upon TMZ treatment (200 ug mL−1, 72 h), bulk wst-1 assay
results at one-week post-treatment exhibited a significant
decrease in viability across all HA conditions (Fig. 7d).
Correspondingly, metabolic imaging showed a significant
increase in redox ratio post drug treatment across all ECM
conditions and of both the scaffold and outer edge gel cell
populations (Fig. 7c). However, the cellular patterns observed in
the redox ratio images revealed cell population-specific differ-













































Fig. 4 RNA-sequencing data for glioblastoma 3D bioengineered cultures. a Heatmap along with clustering based on extracellular matrix generated using
FPKM (Reads Per Kilobase of transcript per Million mapped reads) values. b Principal component analysis (PCA) plot. FECM- Fetal ECM+ collagen I,
AECM- Adult ECM+ Collagen I, CLG1-Collagen I. False discovery rate (q)= 0.04, p-value= 0.00008; n= 2 per condition Source data are provided as
Supplementary Data 1
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concurrent loss in cell feature morphology and significantly
increased redox ratio hues in comparison to TMZ treated scaffold
populations (Fig. 7c, e). There was also significant cell loss with
this population as observed macroscopically by not many visible
cells within the outer gel across all conditions post TMZ
treatment (seen during imaging when sampling outer edge gel
areas) (Fig. 7a). This finding is supportive of the detected
metabolic patterns of the outer edge gel populations, as more
actively proliferating populations would be highly targeted by the
DNA alkylating TMZ treatment. Similarly, the detection of
undisturbed cellular clusters in our cultures hints towards TMZ-
resistant populations, a finding matching clinical observations of
high rates of TMZ patient non-responders40.
Detailed pixel-wise analysis of the redox ratio images further
revealed four distinct redox distributions (defined as Components
1–4, with Component 1 and Component 4 centered at the lowest
and highest redox ratios, respectively), where Components 3 and
4 had significantly greater relative weight with the cells in the
outer edge gel, suggesting increased oxidative stress and apoptotic
trends in this population post drug treatment26 (Supplementary
Fig. 9). In addition, these cells with concurrent loss in cell feature
morphology and increased redox ratio were confirmed to be
indeed apoptotic by live caspase 3/7 positive staining (Supple-
mentary Fig. 10). Together, these data indicate that the outer edge
gel cell population was more drug-responsive to TMZ treatment
than the immobile population in the scaffold region. Thus,
metabolic imaging revealed tumor growth differences across
ECM conditions (HA vs. CLGI base hydrogels), and varying
response of metabolically heterogeneous cell populations post
drug treatment. Such differences were not discernable by bulk
viability assays.
Lipid droplets observed in 3D bioengineered GBM cultures.
We observed the production of lipid-containing droplets within
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Fig. 5 Cytokine and MMP/TIMP media profiling from 3D bioengineered cultures. a MMP/TIMP release profile (reported in pg mL−1) of 3D ependymoma
cultures infused with CLG1-based hydrogels. n= 5 pooled samples per condition. b MMP/TIMP release profile (reported in pg mL−1) of 3D GBM cultures
infused with CLG1-based hydrogels alongside 3D GBM constructs with no hydrogel added. n= 5 pooled samples per condition. c Cytokine release profile at
1 mo of 3D GBM cultures infused with CLG1-based hydrogels (reported as fold change over control media). n= 7 pooled samples per condition. d Cytokine
release profile at 6.5 mo of 3D GBM cultures infused with HA-based hydrogels at 5.5 mo time point (reported as fold change over control media). n= 5
pooled samples per condition. Supplementary Table 1 lists the full forms of the cytokine abbreviations. Source data are provided as a Source Data file
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imaging. These droplets in comparison to adjacent GBM cells had
a much higher fluorescence lifetime (Fig. 8b, left panel), which
has previously been indicated for lipid droplets in adipose tis-
sue41. Additionally, BODIPY dye that stains for neutral lipids was
utilized, and Coherent Anti-stokes Raman Spectroscopy (CARS)
was employed since it can delineate the morphochemical prop-
erties of all lipid droplets in unstained samples42. The lipid sig-
nature of the observed droplets was confirmed both by CARS
targeting the C–H molecular vibrations (Supplementary Movie 1)
and BODIPY staining (Fig. 8b, middle panel). There were few to
no lipid droplets (LDs) visible in the 3D scaffold GBM cultures
lacking a hydrogel and in tumor spheres grown by the traditional
serum-free sphere culture methods, respectively. The LDs were
found to aggregate mostly extracellularly. The presence of these
extracellular LDs may contribute to the observed lower drug
sensitivity of specific sub-populations of GBM cells within the
silk-HA constructs, consistent with a recent report linking an
increase in cytosolic lipids to TMZ resistance in GBM43.
To our knowledge, this is the first report to capture the
accumulation of LDs with primary GBM cultures in vitro,
whereas previously only shown in vivo by magnetic resonance
imaging in exclusively high grade GBM as opposed to low grade
gliomas or healthy brain tissue44. Thus, through the recapitula-
tion of lipid-containing droplets in the 3D brain-ECM-containing
microenvironment with patient-derived GBM cells, we provide a
robust system to examine pathophysiological behaviors of tumors
that could not be captured in previously existing models.
Discussion
The competition between tumor cell cohesion and interactions
with the surrounding ECM is purported to dictate the invasive
behavior of brain tumors and their drug sensitivity45. In this 3D
bioengineered brain tumor model, the silk protein scaffolds
infused with ECM hydrogels better represent the in vivo envir-
onment by supporting a wide range of tumor phenotypes, i.e.,
stationary or migratory, as single cells or spheres depending on
tumor types/stages, while minimizing model-specific artifacts
such as spheres’ aggregation in scaffold-free conventional sus-
pension cultures. Our previous studies utilizing 2D adherent and
neurosphere cultures46 demonstrated the presence of hetero-
geneous stem cell populations that contribute to tumor progres-
sion47. Notably, in these early studies where ependymoma and
GBM were used to define conditions for expanding patient cells
without losing their stem-like subfractions ex vivo, ECM-
dependent performance of patient cells was observed. Expan-
sion as adherent cultures over sphere cultures, particularly on
laminin-poly-L-ornithine coated plastic dishes was observed to be
more favorable for the growth and maintenance of stem-like cell
subfractions ex vivo (Supplementary Fig. 11).
Here, we extended these insights to a 3D bioengineered brain
tumor tissue model with a complex ECM microenvironment
achieved by the incorporation of decellularized brain-ECM.
Whereas authentic human brain-ECM is presently unavailable, we
infused native brain-ECM cues in our 3D tissue model by supple-
menting porcine-derived fetal and adult brain ECMs into a base
hydrogel (collagen type I or HA hydrogels). The rationale of
choosing a 1:3 ratio of ECM to collagen type I/HA was threefold: to
obtain a stable hydrogel that could be maintained in culture, to have
a stiffness in the range of native brain (0.1–1 kPa48) and to simulate
the upregulation of collagen type I and/or HA in the tumor
microenvironment, each of which was determined to be approxi-
mately 2–3-fold higher in ependymoma/GBM when compared to
healthy brain tissue49,50 (Supplementary Fig. 12). In doing so, we
provide a suitable starting point for addressing the complex tumor
cells-brain-ECM interactions, particularly from different develop-
mental stages in the context of tumor progression.
Previously, we have described that rat cortical neuronal cul-
tures resulted into more mature neurons within brain-ECM-
containing culture conditions51, exhibiting a different response to
these decellularized matrices in comparison to the patient tumors
as reported here. In the current study, with pediatric ependy-
moma and adult GBM as examples, we show distinctive growth
behaviors of the primary tumor cells in the same 3D ECM
microenvironment, suggesting tumor-type-specific interactions
with the matrix. Additionally, the cell-ECM interactions involved
distinct cell-secreted signals in terms of MMPs/TIMPs, corre-
sponding to each tumor type within the same ECM micro-
environment. Patient ependymoma cultures exhibited higher



















Fig. 6 Live metabolic imaging of glioblastoma cultured in 3D silk-CLG1 or silk-HA constructs. a Macroscopic views of the GBM spheres within silk-CLG1 or
silk-HA constructs. Scale bar, 2 mm. The yellow arrows point at spontaneously forming sphere-like structures from the seeded tumor cells post dissociation.
b Representative redox ratio images from endogenous metabolic co-factors FAD and NADH within GBM cells in 3D constructs at 1.5 mo post-gel addition
and 7 mo post cell seeding. Scale bar, 50 µm. Image heatmap reflects varying redox ratio intensities. c Quantitative intracellular signal evaluation validated
the existence of metabolic differences between HA and CLG1 conditions, with a statistically significantly higher redox ratio (FAD/FAD+NADH) in CLG1
cultures. Unpaired two-tailed t-test, p= 0.0271, df= 4, t= 3.406, n= 3 per condition (Multiple areas imaged per condition= 3–8; total imaged in CLG1= 13,
HA= 19). Error bars indicate mean ± s.d, Source data are provided as a Source Data file
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correlating with the known prognostic value of MMPs in pedia-
tric ependymomas31. On the other hand, upregulated TIMPs
(Fig. 5b) with a known MMP activation role, can likely explain
why the GBM cells were more migratory in fetal ECM-enriched
constructs and also indicate a complex balance between TIMPs/
MMPs34 leading to morphologically/metabolically heterogeneous
populations within GBM cultures52.
When combined with transcriptomic profiles of the tumor cells
in different microenvironments, these interactions showed simi-
larities that clustered by tumor types as well as ECM conditions.
Additionally, many ECM contributors, including CSPGs, were
differentially produced depending on the brain tumor type and
the culture microenvironment. Furthermore, the highest LDH
















































Viability assay: GBM 7.5 mo 3D cultures





























Outer edge gel scaffold Outer edge gel scaffold
Fig. 7 Live metabolic imaging of glioblastoma cultured in 3D silk-HA-ECM constructs. a Macroscopic views of the GBM spheres within silk-HA-ECM
constructs, post- DMSO (no treatment control) or temozolomide (TMZ) exposure. Scale bar, 2 mm. b Representative redox ratio images from endogenous
metabolic co-factors FAD and NADH within GBM cells in 3D silk-HA constructs at 2 mo post-gel addition and 7.5 mo post cell seeding, with right panel
showing images taken within the scaffold portion and left panel with images taken in the outer edge gel of the construct, respectively. Scale bar, 50 µm.
Image heatmap is the same for panel images and reflects varying redox ratio intensities. c Redox ratio quantification corresponding to outer edge gel areas
and within scaffold areas, post-DMSO or TMZ exposure. Unpaired two-tailed t-tests between separate pairs; n= 3 per condition (multiple areas imaged
per condition),**p < 0.0081, *p < 0.0321, df= 4, t > 3.228. d Wst-1 bulk viability assay at 7.5 mo in 3D GBM silk-HA cultures post- DMSO and TMZ
exposure. Unpaired two-tailed t-test between separate pairs, *p < 0.0221, df= 4, t > 3.635. e Representative redox ratio images within GBM cells in 3D silk-
HA constructs at 2 mo post-gel addition and 7.5 mo post cell seeding. 2-photon signals were obtained post- 72 h exposure to either DMSO or TMZ. Scale
bar, 50 µm. Error bars indicate mean ± s.d, Source data are provided as a Source Data file
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growth factors are suggestive of necrosis following increased
senescence of differentiated populations, which in turn has the
potential to render tumor stem-like populations more aggressive
via paracrine signaling52. Thus, regardless of the tumor type, fetal
brain-ECM-containing cultures showed more favorable growth as
measured with a wide range of readouts, indicating a complex
native brain-ECM-containing microenvironment to be better
than base hydrogel alone.
Initiation in fetal ECM-supplemented collagen type I/HA
hydrogel appeared to boost the initial in vitro growth of primary
tumor cells. Fetal brain-ECM is distinct in composition from the
mature adult brain-ECM. Fetal brain-ECM has a higher content
of total collagens and GAGs than mature adult brain-ECM
(which has higher ratio of sGAGs to collagens); we reported this
difference in a previous manuscript51. Many collagens (collagens
I, IV, VI) and GAGs (CSPG4, HA) are known to be upregulated in
brain tumors in comparison to mature adult brain (Supplemen-
tary Figs. 12, 13). GAGs (CSPGs, HSPGs) play an important role
in tumor progression, as shown by the work of Phillips and
others7,53. There are also specific hints in literature towards HA
concentration in glioma matching that in embryonic brain tis-
sue13 and cancer as an embryological phenomenon54, suggesting
why the fetal brain-ECM-enriched in collagens and GAGs such as
CSPGs, HA55,56 best supported tumor growth in vitro in our 3D
cultures. The adult brain-ECM, on the other hand, although
reported to have a higher ratio of sGAGs to collagens and
comparable to mature adult brain, due to the additional presence
of GAGs and many other ECM proteins likely still modulates/
enhances tumor-ECM interactions than just plain collagen I/HA.
Our study demonstrates the utility of high resolution metabolic
imaging to identify morphologically/metabolically distinct tumor
cell populations and labile events, such as LDs. The novel finding
of GBM cell-produced LDs in the 3D microenvironment can
perhaps be attributed to the stabilization of the extracellular
droplets by the amphiphilicity of the high molecular weight silk
fibroin protein of the scaffold. LD presence is an emerging
characteristic of GBM observed in glioma patient samples and
correlated with poor survival57–60. Although preliminary, as
detailed analysis is still needed for validation, this is powerful as it
applies to monitoring other tumor types prospectively, perhaps in
conjunction with patient chemotherapy in future. While our
optical redox ratio assessments can provide highly sensitive and
non-invasive assessments of metabolic differences and the spa-
tially heterogeneous responses of cells, there are limitations in
terms of the specificity with which these measurements alone can
identify the origins of such changes. In the future, optical meta-
bolic imaging could be combined with novel exogenous metabolic
activity sensors that may provide such insights61. Alternatively,
terminal imaging and mass spectrometry measurements may be
used to gain more mechanistic insights62. Future work would also
require laser capture microdissection (LCM) and single cell
profiling alongside longitudinal live imaging since many of the
contributing factors are temporal.
Our work addresses the complexity of brain tumor-ECM
interactions, an active area of research in need of more in-depth
knowledge and tools. The compartmentalized design allows for
examination of single or combinations of different brain-relevant
matrices. Specifically, TPEF imaging combined with bulk
solution-based assays allowed for a range of fast readouts. For
instance, metabolic imaging results combined with the cytokine
profiles pointed towards the critical roles played by both HA and
the components in fetal brain-derived ECM for bolstering GBM
aggressiveness in vitro, consistent with the known roles of HA in
GBM microenvironment19,63. This result suggests that we can
modulate ECM cues, based on changes during development, in
the future to prevent certain tumor cell behaviors. Together, these
findings have provided many novel insights to the reciprocal
signaling between a brain tumor and its ECM microenvironment
that are relevant to understanding the growth and drug sensitivity
of 3D tumors. To further increase relevance of these in vitro
tumor tissue models to the in vivo environment will need
incorporation of non-tumor cells, present in the tumor micro-
environment. We tested the feasibility of doing so by combining
3D bioengineered cultures of differentiated neural stem cells with
patient tumor cells (Supplementary Fig. 14). One approach to
investigate the interactions between the neoplastic and non-
neoplastic cells, by exploiting the tunability of these 3D cultures
would involve the assembly of two concentric rings of scaffolds
seeded with each of the cell types before the introduction of ECM
hydrogel.
Feasibility of multiple dosage regimens and repeated manip-
ulation, followed by metabolic imaging for continuous tracking of
the same drug treated cultures over time, suggests potential utility
of this robust system for drug screening. We acknowledge that we
have described this platform using two different primary brain
tumors. Considering the low frequency of patients, this made
expanding the study to a larger sample size challenging. Our goal
was to present the utility of this new tissue model in evaluating
patient tumor-ECM interactions. Studies involving more patient
tumor samples will be useful to increase confidence in the broader
applicability of this new tissue model for drug screening and
mechanistic studies. Future studies should involve utilizing this
scaffold-based 3D tumor culture platform with multiple fresh
samples alongside low passage tumor cells expanded in serum-
free media. A personalized approach, as we have demonstrated in
TMRE    BODIPY






Fig. 8 Lipid droplets in glioblastoma cultured in 3D silk-HA-ECM
constructs. a Spread of individual GBM spheres of varying sizes as indicated
by TMRE staining, within the silk-HA constructs and a zoomed in area in
the right panel, where droplets are visible as indicated by the yellow arrows.
The droplets are white spherical structures against silk scaffold, which is
also seen in white corresponding to the fluorescence signal. Stitching and
3D rendering done to obtain the images. Scale bar, 2 mm. b Confirmation of
the droplets visible within the silk-HA constructs to be lipid-containing, as
indicated by an increased fluorescence lifetime in comparison to GBM cells
captured by 2-photon lifetime imaging (leftmost panel, one plane), by
CARS signal targeting the C–H stretch shown for droplets (bright red) and
cells (faint red) (middle panel), and by BODIPY staining of lipid droplets
(green) against GBM cells stained by TMRE (red) captured by confocal
imaging. CARS and confocal images are presented as maximal projections
of 3D z-stacks to optimize visual contrast. Scale bar, 20 µm
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this study, can provide a tool to enable more systematic studies
of diverse types of brain tumors. Importantly, these studies
demonstrate that the tissue model system is highly tunable,
amenable to scale-up and easy to adapt to a wide range of bio-
logical assays and label-free imaging.
Materials and methods
Primary human brain tumor culture. Tumor tissue was harvested during resec-
tion surgery after patient consent in accordance with the IRB-12418 protocol,
approved by the Institutional Review Boards of Tufts University and Connecticut
Children’s Hospital. Following de-identification, each patient tumor sample was
transferred in ice-cold DMEM-F12 supplemented with 1% antibiotic-antimycotic
(Sigma–Aldrich). Resected tumor tissue was portioned for immediate culturing,
and for cryopreserving for future cultures. For viably freezing, each tumor sample
was chopped into ~2 mm2 pieces and frozen in equal volumes of growth media and
fetal bovine serum (FBS) supplemented with 5% dimethyl sulfoxide (DMSO). All
the frozen tumor samples were completely used during the course of this study.
Anaplastic ependymoma (Grade III) from a pediatric patient (2-year-old female
patient) was mechanically dissociated by sequential pipetting using 10 mL, 5 mL,
2 mL, and 1 mL pipettes until a homogenous cell suspension was obtained. The cell
suspension was centrifuged at 1200 r.p.m. for 5 min, followed by resuspension in
either FBS free growth media, EGM 2MV-NBM [50% complete neurobasal (NBM)
containing base neurobasal with 1% glutamax, 1% B27 supplement, 1% antibiotic-
antimycotic; 50% endothelial growth media (EGM 2MV BulletKit minus FBS)]
or FBS-containing growth media (DMEM F12 with 10% FBS and 1% antibiotic-
antimycotic).
For the adult GBM sample (55-year-old male patient, primary IDH-wild-type,
EGFR-positive), the tumor tissue was minced into 1 cm2 pieces and incubated in
TrypLE Select enzyme (Thermo Fischer Scientific, 12563029) for 15 min at 37 °C,
with regular pipetting every 5 min. Upon completion of incubation, twice the
volume of GBM growth media was added to the tumor sample. GBM growth media
consisted of vitamin-A deprived neurobasal, 1% B27 supplement, 1% antibiotic-
antimycotic and the following human growth factors: 20 ng mL−1 epidermal
growth factor (EGF, Peprotech AF10015100UG), 20 ng mL−1 basic fibroblast
growth factor (bFGF, vWR 100-18B-100UG), 10 ng mL−1 heparin, 20 ng mL−1
platelet-derived growth factor-BB (PDGF-BB, Peprotech 100-14B). Next, the
minced and digested GBM samples in media were further mechanically dissociated
by pipetting using a 1 mL pipette with a broad tip. Since the adult tumor tissue was
much more fibrous and stiffer than the pediatric samples, a balance had to be
obtained between the pipetting repetitions and complete dissociation of the tumor
tissue. Once a relatively homogeneous cell suspension was obtained, it was
centrifuged at 1200 rpm for 5 min and aspirated to remove any TrypLE Select
enzyme, followed by resuspension in GBM growth media.
Additional steps involved filtering of the adult GBM cell suspension using a
100 µm cell strainer to remove undigested tissue debris. The filtrate was plated on
2D laminin and Matrigel coated plates, as well as grown as spheroids in low
adhesion six-well plates. Laminin (Sigma, 11243217001) and Matrigel (Corning,
354277) coatings were prepared by performing dilutions in PBS and DMEM,
respectively. The incubation period for the coatings was either overnight at 4 °C or
~2 h at 37 °C. During the passaging of the 2D cultures, TrypLE Select enzyme was
used to detach cells and frozen stocks were created from the early passages. For the
initial media changes of the spheroid cultures, 40 um cell strainers were used to
retain the formed spheroids and the filtrate with single dead cells was discarded.
Eventually, to avoid losing spheroids that remained adhered to the cell strainer,
media changes for spheroid cultures involved centrifuging the spheroids and
resuspending them gently in half fresh media.
3D bioengineered brain tissue model with primary tumor cells. The assembly
of the bioengineered cortical tissue was performed as previously described with
further optimization64. Briefly, silk porous 3D scaffolds were coated with 0.1 mg
mL−1 poly-D-lysine (Sigma–Aldrich) either overnight at 4 °C or for 2 h at 37 °C.
The scaffolds were washed with PBS three times and incubated in media at 37 °C
for at least 30 min to equilibrate the scaffolds for cell seeding. Subsequently, tumor
cells from either the mechanically dissociated pediatric tumor, TrypLE Select
digested adult GBM or single cells obtained from primary GBM expanded as
spheroids (P2) were seeded in the 3D ring-shaped silk scaffolds. After overnight
incubation of 100 µL tumor cell suspension per scaffold in a 96-well plate, the
unattached cells were washed away with the growth media for the corresponding
tumor type. Next, the tumor cell-seeded scaffolds were infused with 3 mgmL−1 rat
tail collagen type I (Corning) or HA hydrogels.
For the generation of ECM-collagen type I hydrogels, porcine brain-ECM from
different developmental stages was obtained via a previously developed
decellularization process51. The lyophilized ECM was solubilized with 1 mgmL−1
pepsin from porcine gastric mucosa (Sigma–Aldrich) in 0.1 N hydrochloric acid
(Sigma–Aldrich). The solubilization time for fetal and adult ECM at room
temperature was ~16 and 24 h, respectively. Once solubilized, the ECM was mixed
with 10x DMEM (final 1x in gel) and neutralized using 1M NaOH
(Sigma–Aldrich). The neutralized ECM solution was mixed with 3 mgmL−1 rat tail
collagen type I (Corning) for a final ECM concentration of 1000 μg mL−1 and the
gelation process started using NaOH. The ECM-collagen solution was kept on ice
until complete gelation was required and was used within 2 h of preparation. For
HA hydrogels, 5.5% tyramine-substituted HA (Lifecore) was reconstituted sterile at
10 mgmL−1 in ultrapure water overnight at 4 °C on a shaker. To obtain HA gels of
~ 1kPa bulk modulus, final optimized concentrations of HA (4 mgmL^−1),
horseradish peroxidase (1 U mL−1), hydrogen peroxide (0.005% v/v) and pH
adjusted 10x DMEM (1x in gel) were mixed together on ice. The remaining volume
was adjusted by addition of ultrapure water. In the case of ECM-HA hydrogels, 10x
DMEM (with a final concentration of 1x in gel) was added to solubilized ECM,
which was further pH adjusted and then mixed with the rest of the components.
HA hydrogels were prepared in small volumes (~1 mL) due to their rapid gelation
time and added to scaffolds immediately. After introduction within the cell-seeded
scaffolds, the gelation was completed within 30 min at 37 °C, following which more
media was added to each well with the constructs. The next day, each of the ECM-
containing tumor cell-seeded 3D constructs was moved to a larger well of a 24-well
plate with sufficient media.
We tested the response of the 3D tumor cultures to the chemotherapy drugs
that were administered to the patients, cisplatin (Sigma–Aldrich, 232120) and TMZ
(Selleckchem, S1237) for anaplastic ependymoma and GBM, respectively.
Anaplastic ependymoma samples were treated at 4 mo with multiple doses (2–3) of
cisplatin over a period of 2 weeks; while GBM samples were treated at ~7mo in
culture with a single dose of 200 µM TMZ for 72 h. We started with TMZ
concentrations based on published in vitro concentrations, which were tested
mostly in 2D glioblastoma cell lines65. We performed in vitro screening to check
for TMZ concentration in 3D cultures that reduced viability, such that we could
image the changes by metabolic imaging. Control samples were exposed to DMSO
in media for the same time frame as drug treated samples.
Co-culture with differentiated healthy hiNSCs. 3D bioengineered constructs
with healthy differentiated induced neural stem cells (hiNSCs) were generated
using a similar methodology as described for tumor cultures and previously
detailed for hiNSCs in the silk-scaffold system66, with further optimization. The
differentiating hiNSC constructs were transfected with a viral vector, AAVdj-hSyn-
eYFP (Charu Ramakrishnan, Karl Deisseroth, Stanford University), such that the
differentiated synapsin (Syn)-expressing neurons would express eYFP (Yellow
fluorescent protein). GBM cells expanded as spheres from the patient-tumor were
placed in close proximity to the 3D hiNSC constructs 7 mo post-differentiation.
Before starting the co-cultures, the GBM cells were separately incubated with
5-aminolevulinic acid (5-ALA, Sigma–Aldrich A3785) for 48 h, for visualization
following 5-ALA preferential accumulation. The invasion of healthy hiNSC cul-
tures by the GBM cells and vice versa was observed 48 h post co-culture, by
simultaneous live imaging of the differentiated hiNSCs by eYFP and GBM by
5-ALA.
Viability assay. Cell proliferation was performed via WST-1 assay
(Sigma–Aldrich) according to the instructions provided by the manufacturer, to
assess tumor cell proliferation. Briefly, the samples were incubated for 1 h with
WST-1 reagent diluted 1:10 (v:v) in culture medium, followed by a reading of the
medium absorbance with plate reader (Molecular Devices) at 450 and 600 nm.
Fresh medium was used as a baseline control and its average absorbance was
subtracted from the value of the samples. A total of N= 3−6 samples/condition
were used in the assay depending on the tumor type.
Lactate dehydrogenase assay. Lactate dehydrogenase (LDH) released into media
by ruptured tumor cells was used as a measure of cell death at different time points
during the 3D culture without having to sacrifice the samples. LDH assay was
performed according to the manufacturer instructions (Sigma–Aldrich). Briefly,
culture medium was mixed with the assay reagents in a 1:2 ratio. Following 30 min
incubation at room temperature, the reaction was stopped by addition of 1 N HCl.
The absorbance was measured at 490 nm and 690 nm. Once again, fresh medium
without any construct was used as a baseline control and its average was subtracted
from the sample values. A total of N= 3−6 samples/condition were used in the
assay depending on the tumor type.
CSPG release ELISA. CSPGs released by the tumor cells in media were measured
using an ELISA based assay67. Media samples from the 3D tumor constructs were
incubated overnight at 4 °C in a 96-well immuno plate (Thermo Fischer Scientific).
Alongside the sample media incubation, chicken extracellular CSPGs (Millipore,
CC117) were used over a range of serial dilutions for the generation of standard
curves. Following washes with PBS-Tween, monoclonal anti-chondroitin sulfate
antibody produced in mouse/clone CS-56, ascites fluid (Sigma–Aldrich, C8035)
was added for overnight incubation at 4 °C. After the next round of washes, HRP
conjugated goat anti-mouse secondary antibody (Abcam) was incubated at room
temperature for 2 h. TMB (3,3′,5,5′-tetramethylbenzidine) 1-C Substrate (Fischer
Scientific) was introduced following the last round of washes with PBS-Tween.
Finally, after the color developed for 10 min at room temperature, the reaction was
stopped with 1 N HCl. The absorbance readings were measured at 450 nm wave-
length and the fresh media readings were subtracted from the sample readings. The
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standard curve was utilized for calculating the quantities of CSPGs released in the
different conditions and reported in pg mL−1.
Immunostaining. The samples were fixed at different time points with 4% par-
aformaldehyde (PFA) solution in PBS (Santa Cruz Biotechnology). Fixation time
was 10 min for 2D samples and 20–30 min for the 3D constructs. The cells were
stained with glial fibrillary acidic protein (GFAP)primary antibody (Sigma G3893)
at a 1:500 dilution and incubations were performed at 4 °C overnight, while the
secondary antibody (Invitrogen A-11001, 1:250 dilution) incubations were carried
out at room temperature for 2 h. The stained samples were imaged using the Leica
SP8 confocal microscope with ×10 or ×25 objectives.
Live mitochondrial imaging. 2D ependymoma cells or 3D ependymoma con-
structs were incubated in media containing diluted TMRE (30 nM) (Thermo
Fischer Scientific) and Mitotracker (300 nM) (Thermo Fischer Scientific) at 37 °
C for 10 min and 1 h, respectively. Following incubation, the samples were
imaged using the Keyence BZ-X700 or the Leica SP8 confocal equipped with an
incubator setup maintained at 37 °C and with 5% carbon dioxide inflow. The
images were taken with ×60 objective using the same exposure time, and light
power across all sample conditions when using the Keyence BZ-X700 for the 2D
samples.
5-ALA imaging. During long-term culture (4 mo) of GBM cells, tumor cell
invasion in different matrices was examined via migration into the ECM filled
central window of the cell-seeded ring-shaped scaffold via 5-ALA (Sigma–Aldrich
A3785) accumulation within tumor cells. 5-ALA was excited at 405 nm and
emission was collected within 620–720 nm, corresponding to the protoporphyrin
IX which accumulates in glioma cells due to low ferrochelatase activity. The 3D
samples were imaged using the Leica SP8 confocal microscope.
RNA sequencing and qRT-PCR. Samples were flash frozen in liquid nitrogen and
stored in −80 oC in individual RNAase free eppendorf tubes until RNA extraction
was performed. All samples were placed on dry ice during extraction, sequentially
disrupted using a liquid nitrogen chilled bio-pulverizer. Between each sample, the
pulverizer was wiped with 70% ethanol to remove remnants of the previous sample,
and between each sample set (different conditions), all the tools were cleaned with
RNAzap. Lysis buffer was immediately added to the powdered frozen sample and
placed on ice. Once all the samples were in lysis buffer on ice, a 22-gauge needle
and syringe were used for sample homogenization one by one using a fresh needle
and syringe every time. All the samples were spun down to remove undigested
material (mainly silk scaffold) and the supernatant was transferred to clean
RNAase free eppendorfs. Following this, the SurePrep All Prep kit (Fischer Sci-
entific) protocol was followed until RNA was eluted from the columns. Preliminary
RNA concentrations were measured using nanodrop (Nanodrop 2000, Thermo
Fischer Scientific) and sent to Jackson labs for Genomic Medicine in Connecticut,
MA for sequencing. Quality control was performed on the RNA samples post
cleanup and DNAase treatment for improved RIN values. Next, a KAPA mRNA
stranded library was generated for RNA sequencing (RNA-seq) on the Illumina
HiSeq 4000.
The raw sequencing data were evaluated at Tufts Genomic Core where the fastq
reads were quality checked, preprocessed and aligned to the reference human
genome, Hg38 using HISAT2. The aligned data were mapped to possible
transcripts using Cufflinks. The final assembled transcriptome or the output FPKM
(Reads Per Kilobase of transcript per Million mapped reads) values were imported
in Qlucore Omics Explorer for visualization and plotting.
For qRT-PCR, RT2 First Strand Kit with an incorporated gDNA removal step
with buffer GE (Qiagen) was utilized for cDNA synthesis from the eluted RNA.
cDNA samples were mixed with RT2 SYBR Green Fluor qPCR Mastermix and
added to the Qiagen RT2 PCR Array (including a housekeeping gene, genomic
DNA control and RT control). PCR was run on BioRad CFX96.
Microarrays for MMP/TIMP and cytokine release. Multiplex Quantibody
matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases (MMP/
TIMP) and cytokine arrays (RayBiotech) were used to semi-quantitatively or
qualitatively compare the proteases/protease inhibitors and cytokines released by
the tumor cells cultured in the 3D bioengineered brain tumor model with different
ECM environments. Small volumes of control media samples/cell culture super-
natants (50 µL or 2 mL) from the 3D constructs were incubated in the capture
antibody spotted glass slides or the membranes, along with the standards provided
that corresponded to known concentrations of the targets for the Quantibody
arrays. This overnight incubation was followed by another overnight step at 4 °C,
involving the biotinylated detection antibody cocktail. Next, streptavidin-
conjugated fluorophore or HRP-streptavidin was added for 1 h at room tempera-
ture. Finally, the slide was disassembled from the removable gasket, dried, and
scanned using a fluorescence microarray laser scanner (Ray Biotech). For the
membrane array, chemiluminescence detection agent was added right before
imaging the membrane.
The human MMP array Q1 (Ray Biotech) allowed for simultaneous detection
of six MMPs and three TIMPs: MMP-1,2,3,9,10,13, TIMP-1,2,4. Additionally,
the human cytokine array C5 (Ray Biotech) was used to determine the release of
80 different growth factors and inflammatory cytokines (Supplementary
Table 1). Protein expression profiles of the pediatric and adult brain tumors
across the varying ECM conditions were quantified using the Q-analyzer
software (Ray Biotech) to obtain the final values in pg mL−1 for the Quantibody
arrays. For the membrane array, chemiluminescence measurements were
quantified using ImageJ and fold change over the control media was reported in
heat maps.
Metabolic imaging of 3D bioengineered brain tumor model. Tissue samples
were imaged with a multiphoton confocal microscope (TCS SP8, Leica) equipped
with a Ti-Sapphire laser and time-correlated single-photon counting electronics.
During imaging, each sample was placed in a well of a glass bottomed (No. 1.5
coverslip) 24-well plate. The imaging chamber was maintained at 37 °C and
humidified along with a continuous supply of 5% CO2. Endogenous two-photon
excited fluorescence (TPEF) images were acquired at 1024 by 1024 pixels with FOV
232.50 µm by 232.50 µm, and 2x zoom using a 25× (0.95 NA) water objective
following excitations at 755 nm and 860 nm for capturing NADH and FAD signals,
460 ± 25 nm (NADH) and 525 ± 25 nm (FAD), respectively.
During endogenous imaging, multiple single planes (n > 3) at varying depths
were acquired within each 3D construct. Power measurements of the laser at the
two excitation wavelengths were taken regularly and used to normalize the signals
during analysis. Incident laser power was ~20 mW at the acquisition focal plane
with a pixel dwell time of 600 ns. CARS imaging targeting the C–H molecular
stretch was also performed on a subset of samples to validate lipid content of the
droplets observed within the GBM cultures. CARS imaging was performed using a
commercial Leica TCS SP8 CARS microscope (Wetzlar, Germany), equipped with
a picoEmerald picosecond laser and optical parametric oscillator (Stokes beam=
1064 nm, 7 ps; pump beam= 770–850 nm, 5–6 ps). Images (295 × 295 microns,
1024 × 1024 pixels, scanning speed of 400 Hz) were acquired with the pump
wavelength set at 816 nm in order to optimally excite the C–H vibrational lipid
stretch at 2856 wavenumbers. The CARS signal was detected at 650 ± 105 nm. A
HC PL IRAPO 40 × /1.10 water immersion objective was used and the average
power of each beam at the sample was held below 50mW to avoid photodamage of
the sample68.
Following the last session of endogenous imaging, some representative samples
were co-stained with CellEvent Caspase-3/7 green (Thermo Fischer Scientific),
NucBlue Dead (Thermo Fischer Scientific), and TMRE (30 nM) (Thermo Fischer
Scientific) reagents to confirm the presence of dead cells and for morphological
comparison post-TMZ treatment. Similarly, a few samples were co-stained with a
NucBlue Live (Thermo Fischer Scientific), BODIPY 493/503 (2 µg mL−1 in PBS)
(Thermo Fischer Scientific) and TMRE (30 nM) to test for the presence of lipids
within the droplets observed during imaging.
Field based redox ratio calculation (FAD/FAD+NADH), an intensity based-
metric, was determined using MATLAB processing routines as described
previously41,69. In brief, all acquired images were normalized for power and
detector gain prior to processing. For a given field, the 755 nm excitation, 460 nm
emission (NADH channel) and 860 nm excitation, 525 nm emission (FAD
channel) were then spatially co-registered by determining the shift maximizing
correlation between the two channels. A mean normalized redox ratio value was
computed for each field as the normalized fluorescence intensity contributions
from FAD over the sum of the intensity contributions from NADH and FAD and
reported as the mean redox value per field of view. Additionally, a lifetime based
filter was utilized to remove silk contributions. Briefly, silk autofluorescence has a
longer fluorescent lifetime during excitation at 755 nm than that of NADH found
in cellular regions. Silk scaffold areas were removed by masking out regions that
possessed lifetime values beyond a cutoff threshold value when this lifetime was
transformed into phasor space (transforming the exponential decay of fluorescence
lifetime with sines and cosines), so that there was minimal loss of cellular
signal23,41,70. The overall image-based redox ratios were measured after drug
treatment with TMZ or control DMSO, and across different ECM conditions. The
signals captured at the excitation/emission pair 755/460 ± 25 nm could be the
contributions of both NADH and NADPH, as these are indistinguishable from
each other. However, we have shown previously NADPH to be present at negligible
levels as opposed to NADH in multiple cell types and settings, and thus we assess
the optical redox ratio as based on the concentrations of NADH and FAD.
We further proceeded with the determination of redox ratio distribution
components using a subset of representative images (n= 3–11). Pixel based redox
ratio histograms were first generated by applying a spatial Gaussian low-pass filter
to each redox map image and then creating 50 bins between redox ratio values 0
and 1. Images from different groups were compiled and used in the gmdistribution.
fit function in MATLAB to fit the aggregate histograms with Gaussian components.
The basic components for the model were determined as an average of means and
standard deviations of 10 iterations. We then fit these basis components to each
histogram and normalized relative weights to sum to 100%. To quantify changes in
redox histograms between groups, image-wise ratios of the various Gaussian
component weights were used (i.e., W1/ (W2+W3+W4), W2/ (W1+W3+
W4), etc.). Component 1 (centered at the lowest redox ratio) is typically associated
with glycolysis, while higher components have been paired to enhanced oxidative
phosphorylation and oxidative stress conditions.
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Statistics. The graphs were prepared, and statistical analysis performed using
GraphPad Prism 7 software (GraphPad, CA, USA). All data are expressed as mean ±
s.d arising from sample size of n ≥ 3. The analysis methods utilized included one-way
ANOVA, followed by Tukey’s post-hoc test to determine the statistically significant
differences for multiple comparisons with one independent variable (ECM, media)
and unpaired two-tailed t-test for comparison of two groups unless stated otherwise
in the figure captions. A 95% confidence interval or 0.05 was used as the threshold
for significance (*p < 0.05) throughout all the statistical tests. Stars associated with
p-values have no bearing on the results and conclusion, and are simply reported as
obtained from Graphpad prism for the ease of showing individual p-values.
Appropriate regression curve was used to fit a trendline on the standard curve
generated for ELISAs, such that R2 < 0.97. During the generation of heat maps with
hierarchical clustering and principal component analysis (PCA) plots from RNA-seq
data, false discovery rate q < 0.2 or p-values < 0.005 were used to identify dis-
criminating variables between comparison groups. Additionally, z-score method,
which centers the data to zero mean and unit variance, was used to scale the data
presented in heat maps corresponding to RNA-seq data22.
Data availability
Source data are available for Fig. 2, 57, and Supplementary Figs. 3, 4, 6, 7–9 in the Source
Data file. Source data for Figs. 3 and 4 are provided as Supplementary Data 1. The
accession code for the RNA-seq data deposited to GEO is GSE134567. Any additional
information is available from the authors upon request.
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